CoChat

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Open access
Chu, David, Paoletti, Costanza, Gersch, Christina, VanDenBerg, Dustin A., Zabransky, Daniel J., Cochran, Rory L., Wong, Hong Yuen, Toro, Patricia Valda, Cidado, Justin, Croessmann, Sarah, Erlanger, Bracha, Cravero, Karen, Kyker-Snowman, Kelly, Button, Berry, Parsons, Heather A., Dalton, W. Brian, Gillani, Riaz, Medford, Arielle, Aung, Kimberly, Tokudome, Nahomi, Chinnaiyan, Arul M., Schott, Anne, Robinson, Dan, Jacks, Karen S., Lauring, Josh, Hurley, Paula J., Hayes, Daniel F., Rae, James M., Park, Ben Ho · 2016 · Clinical Cancer Research
Cited by 177

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Mutations in the estrogen receptor (ER)α gene, ESR1, have been identified in breast cancer metastases after progression on endocrine therapies. Because of limitations of metastatic biopsies, the reported frequency of ESR1 mutations may be underestimated. Here, we show a high frequency of ESR1 mutations using circulating plasma tumor DNA (ptDNA) from patients with metastatic breast cancer. Experimental Design: We retrospectively obtained plasma samples from eight patients with known ESR1 mutations and three patients with wild-type ESR1 identified by next-generation sequencing (NGS) of biopsied metastatic tissues. Three common ESR1 mutations were queried for using droplet digital PCR (ddPCR). In a prospective cohort, metastatic tissue and plasma were collected contemporaneously from eight ER-positive and four ER-negative patients. Tissue biopsies were sequenced by NGS, and ptDNA ESR1 mutations were analyzed by ddPCR. Results: In the retrospective cohort, all corresponding mutations were detected in ptDNA, with two patients harboring additional ESR1 mutations not present in their metastatic tissues. In the prospective cohort, three ER-positive patients did not have adequate tissue for NGS, and no ESR1 mutations were identified in tissue biopsies from the other nine patients. In contrast, ddPCR detected seven ptDNA ESR1 mutations in 6 of 12 patients (50%). Conclusions: We show that ESR1 mutations can occur at a high frequency and suggest that blood can be used to identify additional mutations not found by sequencing of a single metastatic lesion. Clin Cancer Res; 22(4); 993–9. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0943

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 177

Metadata

Authors
Chu, D., Paoletti, C., Gersch, C., VanDenBerg, D. A., Zabransky, D. J., Cochran, R. L., Wong, H. Y., Toro, P. V., Cidado, J., Croessmann, S., Erlanger, B., Cravero, K., Kyker-Snowman, K., Button, B., Parsons, H. A., Dalton, W. B., Gillani, R., Medford, A., Aung, K., Tokudome, N., Chinnaiyan, A. M., Schott, A., Robinson, D., Jacks, K. S., Lauring, J., Hurley, P. J., Hayes, D. F., Rae, J. M., & Park, B. H.
Venue
Clinical Cancer Research
Published
2016-02-14
Volume
22
Issue
4
Pages
993-999
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1799492544
Cited by
177
References
5
FWCI
7.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0943
The paper
Chu, D., Paoletti, C., Gersch, C., VanDenBerg, D. A., Zabransky, D. J., Cochran, R. L., Wong, H. Y., Toro, P. V., Cidado, J., Croessmann, S., Erlanger, B., Cravero, K., Kyker-Snowman, K., Button, B., Parsons, H. A., Dalton, W. B., Gillani, R., Medford, A., Aung, K., . . . Park, B. H. (2016). ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.